Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis

Patent metadata

Field	Value
Publication number	US-11931425-B2
Application number	US-202117566015-A
Country	US
Kind code	B2
Filing date	Dec 30, 2021
Priority date	May 29, 2015
Publication date	Mar 19, 2024
Grant date	Mar 19, 2024

Abstract

Described herein is a method of induced cell death via ferroptosis by nanoparticle ingestion. Moreover, the present disclosure describes the administration of high concentrations of ultrasmall nanoparticles at multiple times over the course of treatment in combination with a nutrient-depleted environment, thereby modulating cellular metabolic pathways to induce cell death by the mechanism ferroptosis. Ferroptosis involves iron, reactive oxygen species, and a synchronous mode of cell death execution.

First claim

What is claimed is:

1. A method of treatment of a subject, the method comprising:
administering nanoparticles at an administered concentration greater than 1 μM to activate the tumor microenvironment, characterized by a pro-inflammatory response surrounding or within tumor tissue as compared to non-treated tumor tissue;
wherein the administered nanoparticles have an average diameter no greater than 15 nm, and
wherein the administered nanoparticles comprise a core comprising silica and a silica shell surrounding at least a portion of the core.

2. The method of claim 1 , wherein the pro-inflammatory response comprises an activation of macrophages.

3. The method of claim 1 , wherein the tumor tissue is glutathione depleted.

4. The method of claim 1 , wherein the tumor tissue comprises an accumulation of lipid peroxidation.

5. The method of claim 1 , the method comprising depriving a tumor tissue of hormones.

6. The method of claim 5 , wherein the tumor tissue is deprived of hormones via castration.

7. The method of claim 1 , wherein the tumor tissue is selected from the group consisting of renal, prostate, melanoma, pancreatic, lung, fibrosarcoma, breast, brain, ovarian, and colon tumor tissue.

8. The method of claim 7 , wherein the tumor pancreatic tissue comprises BxPC3 cells.

9. The method of claim 7 , wherein the tumor lung tissue comprises H1650 cells.

10. The method of claim 1 , wherein the nanoparticles have an average diameter no greater than 10 nm.

11. The method of claim 1 , wherein the nanoparticles have an average diameter from about 5 nm to about 7 nm.

12. The method of claim 1 , wherein the nanoparticles comprise from 1 to 20 targeting moieties, wherein the targeting moieties bind to receptors on cells.

13. The method of claim 1 , wherein the nanoparticles comprise from 1 to 20 targeting moieties, wherein the 1 to 20 targeting moieties comprises alpha-melanocyte-stimulating hormone (αMSH).

14. The method of claim 1 , wherein the nanoparticles comprise a targeting moiety.

15. The method of claim 1 , wherein the nanoparticles are administered multiple times over the course of treatment.

16. The method of claim 1 , further comprising administering the nanoparticles every 3 or 4 days over the course of treatment.

17. The method of claim 1 , wherein cells of the tumor tissue comprise an intracellular concentration of iron of 8.3 parts per billion (ppb) or higher.

18. The method of claim 1 , wherein cells of the tumor tissue comprise an intracellular concentration of iron of 144.7 parts per billion (ppb) or higher.

19. The method of claim 1 , wherein cells of the tumor tissue comprise an intracellular concentration of iron of 2.58 μM or higher.

Assignees

• Memorial Sloan Kettering Cancer Center
• Univ Cornell

Inventors

• Bradbury Michelle S
• Wiesner Ulrich
• Overholtzer Michael
• Scher Howard
• Ma Kai

Classifications

• A61K47/6929 Primary

  the form being a nanoparticle, e.g. an immuno-nanoparticle · CPC title

• A61K38/22

  Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35) · CPC title

• A61K47/60

  the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title

• A61K47/6923

  the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb · CPC title

• A61K47/6935 Primary

  the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol · CPC title